Compare · BJDX vs DHR
BJDX vs DHR
Side-by-side comparison of Bluejay Diagnostics Inc. (BJDX) and Danaher Corporation (DHR): market cap, price performance, sector, and recent activity on the wire.
Summary
- BJDX operates in Health Care, while DHR operates in Industrials - the two are in different parts of the market.
- DHR is the larger of the two at $163.93B, about 56230.2x BJDX ($2.9M).
- DHR has been more active in the news (18 items in the past 4 weeks vs 6 for BJDX).
- DHR has more recent analyst coverage (25 ratings vs 1 for BJDX).
- Company
- Bluejay Diagnostics Inc.
- Danaher Corporation
- Price
- -
- -
- Market cap
- $2.9M
- $163.93B
- 1M return
- -
- +0.67%
- 1Y return
- -
- +5.33%
- Industry
- Medical/Dental Instruments
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 18
- Recent ratings
- 1
- 25
Bluejay Diagnostics Inc.
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Latest BJDX
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
- SEC Form 8-K filed by Bluejay Diagnostics Inc.
- Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
- SEC Form 8-K filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
Latest DHR
- Executive Vice President Milosevich Gregory M sold $484,302 worth of shares (2,100 units at $230.62), decreasing direct ownership by 9% to 22,367 units (SEC Form 4)
- Executive Vice President Mcgrew Matthew exercised 17,385 shares at a strike of $88.24 and sold $4,097,452 worth of shares (17,385 units at $235.69) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Danaher Corporation
- Why the Next Edge in Antibody Discovery May Be What Labs Remember
- Integrated DNA Technologies and Aldevron Launch New mRNA Solutions to Simplify Base and Prime Editing
- Director Dewan Feroz was granted 144 phantom shares (SEC Form 4)
- Director Zerhouni Elias A. was granted 199 phantom shares (SEC Form 4)
- Director Filler Linda was granted 15 phantom shares (SEC Form 4)
- Director Stevens Raymond C was granted 153 phantom shares (SEC Form 4)
- Director List Teri was granted 13 phantom shares (SEC Form 4)